Eye-Disease Focused Kodiak Sciences Is A Promising ‘Turnaround Story For 2025’: Analyst Upgrades Stock
Jefferies has upgraded Kodiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company focused on retinal (eye) diseases.
Kodiak’s lead investigational medicine, tarcocimab, is an anti-VEGF antibody biopolymer conjugate under development for high-prevalence retinal vascular diseases.
Tarcocimab is currently being studied in two Phase 3 trials, GLOW2 in diabetic retinopathy and DAYBREAK in patients with wet age-related macular degeneration (wet AMD). Both studies are actively enrolling patients.
Jefferies upgraded Kodiak Sciences from Hold to Buy. The analyst writes that Kodiak Sciences is gaining investor interest as it enters a pivotal phase.
The company’s turnaround story for 2025 looks promising, with Phase 3 trials in wet AMD progressing well and showing strong potential.
Adding to the excitement, upcoming VEGF/IL-6 data for macular edema secondary to inflammation (MESI) (inflammation) could open doors to new …
Full story available on Benzinga.com